Long Noncoding RNAs: Clarity or Confusion?
Because They Are Such Elusive Prey, lncRNAs Have Yet to Emerge as Therapeutic Targets
Markets Expand for Single-Use Bioreactors
Biobags Offer Advantages Over Fixed-Tank Systems
The Challenges of Harmonizing Biomarker Data
Why Trial Success Depends on It
Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
Significant progress is being made toward the development of an effective HIV-AIDS vaccine. In autumn 2009, a collaborative effort between the Ministry of Health in Thailand, the U.S. Military, and the U.S. National Institute of Allergy and Infectious Disease announced the first encouraging results from an efficacy trial—31% prevention of infection in a 16,402-person community-based trial in Thailand. With this encouraging news in the background, several companies are working toward an AIDS vaccine. So, when do you think one will be approved in the U.S.?